Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: The present application provides evidence that a combined blockade against alpha-4 integrin and MCAM is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an MCAM antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease.

Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of VLA-4 blocking agent treatment. These methods comprise detecting the level of L-selectin (CD62L) and optionally LFA-1 expressing T cells in a sample from the subject.

Abstract: The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing ?4-integrin and/or VLA-4 blocking agent treatment for suspension of the treatment and a method of stratifying a subject undergoing Highly Active Antiretroviral Therapy (HAART) for alteration of HAART. These methods comprise detecting the level of P-selectin glycoprotein ligand-1 (PSGL-1) expressing T cells in a sample from the subject.

Abstract: The converter system couples two high voltage three-phase networks. Two converter transformers are associated with each network to be coupled. Each transformer has secondary windings. One secondary winding associated with a first network is Y-connected while the other is delta-connected. The converter transformers operate on a three-phase full wave rectifier with twelve semiconductor rectifier components. The arrangement of valve towers, a stacking of semiconductor components, is designed to keep a base area or a so-called valve housing in which the valve towers are accommodated as small as possible. The semiconductor components are arranged in uniform modular assemblies and may be stacked as modular components having insulating spacings between components which are also uniform. A tower of uniform modules is formed in association with each of the phases of the three-phase secondary windings of the converter transformers. The number of modules defines the number of stories of the tower.

Abstract: A direct current tight coupling is provided for connecting two asynchronous high-voltage three-phase power systems which includes a three-phase full-wave static converter assembly assigned to each of the power systems to be connected, with static converter transformers and controllable semiconductors, which are controlled by a central electronic control unit so that the input-side static converter assembly functions as a rectifier and the output-side static converter assembly as an inverter. The controllable semiconductors of a functional group are mounted atop each other forming identical static converter towers. The towers are connected together at the same pole on the d.c. side and on the three-phase side with the assigned Wye- and Delta-connected secondary sides of the static converter transformers. Each of the full-wave semiconductor subassemblies assigned to the four secondary sides of the static converter transformers form a static converter tower.